The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study).
 
Yoshimasa Shiraishi
No Relationships to Disclose
 
Haruko Daga
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie; Astellas Pharma; AstraZeneca; Chugai Pharma; Pfizer
 
Satoshi Ikeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Akito Hata
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly
Research Funding - AstraZeneca; Boehringer Ingelheim; Lilly; MSD
 
Hideaki Mizutani
No Relationships to Disclose
 
Tomohiro Sakamoto
No Relationships to Disclose
 
Haruhiro Saito
Honoraria - Bristol-Myers Squibb Japan; Nippon Boehringer Ingelheim; Novar Pharma; Ono Pharmaceutical
Patents, Royalties, Other Intellectual Property - AstraZeneca (Inst); Chugai Pharma (Inst)
 
Osamu Hataji
Speakers' Bureau - Boehringer Ingelheim; Novartis
Research Funding - Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Kyorin (Inst); Novartis (Inst)
 
Hiroshi Tanaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD Oncology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Atsushi Horiike
Honoraria - A2 Healthcare; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; MSD Oncology; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Loxo (Inst); MSD Oncology (Inst)
 
Hideo Saka
Honoraria - Amco; AstraZeneca; Becton Dickinson; Boehringer Ingelheim; Boston Scientific; Chugai Pharma; Kyorin; Kyowahakko Kirin; Lilly; MSD K.K; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Harada (Inst); Lilly (Inst); MSD K.K (Inst); Olympus (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Parexel (Inst)
 
Tsuneo Shimokawa
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Masahide Mori
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD; Novartis; Pfizer
 
Katsuya Hirano
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Koichi Azuma
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Ono Pharmaceutical
 
Tetsuya Mitsudomi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Seto
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kissei Pharmaceutical (Inst); Lilly Japan (Inst); Loxo (Inst); Merck Serono (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
 
Nobuyuki Yamamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyorin; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Lilly (Inst); Nippon Boehringer Ingelheim (Inst)
 
Kazuhiko Nakagawa
Honoraria - Astellas Pharma; AstraZeneca Japan; Bristol-Myers Squibb; CareNet; Chugai Pharma; Clinical Trial Co; Daiichi Sankyo; Hisamitsu Pharmaceutical; Kyorin; Lilly; Medical Review Co., Ltd.; Medicus Shuppan Publishers; Merck Sharp & Dohme; NANZANDO Co.,Ltd.; Nichi-iko; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Reno Medical; SymBio Pharmaceuticals; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; YODOSHA; Yomiuri Telecasting Corporation
Speakers' Bureau - Astellas Pharma; Ono Pharmaceutical; Takeda
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); Gritstone Bio (Inst); ICON Clinical Research (Inst); inVentiv Health (Inst); IQvia (Inst); Kissei Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Linical (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International Corp. (Inst); Pfizer (Inst); Quintiles Inc. (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Isamu Okamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)